Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company recently completed a clinical study titled A Phase 1, Open-Label, Multiple-Dose Study to Investigate the Comparability of the Pharmacokinetics of Orforglipron (LY3502970) Single Capsule and Multiple Capsules in Healthy Participants. The study aimed to compare how a single capsule versus multiple capsules of Orforglipron are absorbed and eliminated by the body under both fasted and fed conditions. This research is significant as it evaluates the drug’s safety and tolerability, providing essential data for future development.
The intervention tested in this study was Orforglipron, an experimental drug administered orally. The study assessed its pharmacokinetics, which is how the drug moves through the body, when given in different forms and conditions.
The study followed an interventional, randomized, crossover design without any masking, focusing on basic science. Participants received varying doses of Orforglipron in either single or multiple capsules, under both fasted and fed conditions, to observe differences in drug absorption and elimination.
Key dates for this study include its start on December 13, 2024, and its last update on June 23, 2025. These dates are crucial as they mark the timeline of the study’s progress and completion.
The completion of this study could positively impact Eli Lilly’s stock performance by demonstrating progress in their drug development pipeline, potentially enhancing investor confidence. It also positions Eli Lilly competitively within the pharmaceutical industry as they advance Orforglipron’s development.
The study is now completed, with further details available on the ClinicalTrials portal.